Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: A single-center experience

Ermelinda de Maio, Adriano Gravina, Carmen Pacilio, Gerardo Amabile, Vincenzo Labonia, Gabriella Landi, Francesco Nuzzo, Emanuela Rossi, Giuseppe D'Aiuto, Immacolata Capasso, Massimo Rinaldo, Brunello Morrica, Massimo Elmo, Massimo Di Maio, Francesco Perrone, Andrea de Matteis

Research output: Contribution to journalArticle

Abstract

Background: Few data are available on compliance and safety of adjuvant chemotherapy when indicated in elderly breast cancer patients; CMF (cyclophosphamide, methotrexate, fluorouracil) can be reasonably considered the most widely accepted standard of treatment. Methods: We retrospectively reviewed compliance and safety of adjuvant CMF in patients older than 60. The treatment was indicated if patients had no severe comorbidity, a high-risk of recurrence, and were younger than 75. Toxicity was coded by NCI-CTC. Toxicity and compliance were compared between two age subgroups (

Original languageEnglish
Article number30
JournalBMC Cancer
Volume5
DOIs
Publication statusPublished - Mar 24 2005

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

de Maio, E., Gravina, A., Pacilio, C., Amabile, G., Labonia, V., Landi, G., Nuzzo, F., Rossi, E., D'Aiuto, G., Capasso, I., Rinaldo, M., Morrica, B., Elmo, M., Di Maio, M., Perrone, F., & de Matteis, A. (2005). Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: A single-center experience. BMC Cancer, 5, [30]. https://doi.org/10.1186/1471-2407-5-30